Detalhe da pesquisa
1.
A randomized phase II study of metronomic cyclophosphamide and methotrexate (CM) with or without bevacizumab in patients with advanced breast cancer.
Breast Cancer Res Treat
; 204(1): 123-132, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38019444
2.
Systemic endocrine instigation of indolent tumor growth requires osteopontin.
Cell
; 133(6): 994-1005, 2008 Jun 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-18555776
3.
Brief-exposure to preoperative bevacizumab reveals a TGF-ß signature predictive of response in HER2-negative breast cancers.
Int J Cancer
; 138(3): 747-57, 2016 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26284485
4.
"An addendum to breast cancer": the triple negative experience.
Support Care Cancer
; 24(9): 3715-21, 2016 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27037812
5.
Biomarkers for Predicting Response to Anti-HER2 Agents.
Adv Exp Med Biol
; 882: 155-67, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-26987534
6.
Phase 1b study of the mammalian target of rapamycin inhibitor sirolimus in combination with nanoparticle albumin-bound paclitaxel in patients with advanced solid tumors.
Cancer
; 121(11): 1817-26, 2015 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-25649370
7.
Integrative transcriptome-wide analyses reveal critical HER2-regulated mRNAs and lincRNAs in HER2+ breast cancer.
Breast Cancer Res Treat
; 150(2): 321-34, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25749757
8.
Molecular definition of breast tumor heterogeneity.
Cancer Cell
; 11(3): 259-73, 2007 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-17349583
9.
A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers.
Nat Genet
; 38(9): 1043-8, 2006 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-16921376
10.
Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab.
BMC Cancer
; 14: 326, 2014 May 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-24885187
11.
Requirement for CDK4 kinase function in breast cancer.
Cancer Cell
; 9(1): 23-32, 2006 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-16413469
12.
The renaissance of endocrine therapy in breast cancer.
Curr Opin Obstet Gynecol
; 26(1): 41-7, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24346127
13.
Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2.
JCO Precis Oncol
; 8: e2300407, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38603650
14.
Phase II Study of Erdafitinib in Patients With Tumors With FGFR Amplifications: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K1.
JCO Precis Oncol
; 8: e2300406, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38603651
15.
Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol J.
Clin Cancer Res
; 30(7): 1273-1280, 2024 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38433347
16.
Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E.
JCO Precis Oncol
; 8: e2300454, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38591867
17.
A role for the scaffolding adapter GAB2 in breast cancer.
Nat Med
; 12(1): 114-21, 2006 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-16369543
18.
Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer.
J Clin Oncol
; 41(9): 1638-1645, 2023 03 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-36921335
19.
National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH).
Clin Cancer Res
; 29(8): 1412-1422, 2023 04 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-36662819
20.
Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B.
Clin Cancer Res
; 29(8): 1477-1483, 2023 04 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-36853016